Search
Returning search results with filters:
Remove filter for
Audience: Healthcare
Remove filter for
Category: Health products
Remove filter for
Issue: New safety information
Remove filter for
Issue: Product safety
Remove filter for
Last updated: February 2022
Remove filter for
Last updated: 2022
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 1 of 1 items.
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion
AlertHealth professional risk communication | 2022-02-03